I was thinking more about the side effects of VRTX's drug. I'm not sure how adding side effects to a SOC that already causes huge compliance issues will be received. It seems to me adoption would require a sig higher SVR over 12 months or at least comparable SVR over a shorter course SOC.
I worry that at some point, lower SVR advantages will result in lower use of the drug because of VRTX side effects.
Market Data 
Markets 
AI
